Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial

Lancet

Volumn 360, Issue 9338, 2002, Pages 971-977

  Van Damme, Lut ^a,m   Ramjee, Gita ^b   Alary, Michel ^c,d   Vuylsteke, Bea ^a,e   Chandeying, Verapol ^f   Rees, Helen ^g   Sirivongrangson, Pachara ^h   Mukenge Tshibaka, Léonard ^c,i   Ettiègne Traoré, Virginie ^e   Uaheowitchai, Cham ^j   Abdool Karim, Salim S ^b   Mâsse, Benoît ^c,k   Perriëns, Jos ^l   Laga, Marie ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF QUEBEC   (Canada)

^d Projet SIDA 2   (Benin)

^e Project RETRO CI Abidjan   (Côte d’Ivoire)

^f PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h MINISTRY OF PUBLIC HEALTH   (Thailand)

ⁱ Centre de Santé Cotonou 1   (Benin)

^j Venereal Disease Center Region 12   (Thailand)

^k Fred Hutchinson Cancer Research Center   (United States)

^l UNAIDS   (Switzerland)

^m EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COL 1492; NONOXINOL 9; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHLAMYDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; FEMALE; GONORRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL; VIRUS TRANSMISSION;

EID: 0037190597     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11079-8     Document Type: Article

References (19)

1. Benes S., McCormack W.M. Inhibition of growth of Chlamydia trachomatis by nonoxynol-9 in vitro. Antimicrob Agents Chemother. 27:1985;724-726.
2. Bourinbaiar A.S., Fruhstorfer E.C. The efficacy of nonoxynol-9 from an in vitro point of view. AIDS. 10:1996;558.
3. Hicks D.R., Martin L.S., Getchell J.P., et al. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet. 2:1985;1422-1423.
4. Polsky B., Baron P.A., Gold J.W.M., Smith J.L., Jensen R.H., Armstrong D. In-vitro inactivation of HIV-1 by contraceptive sponge containing nonoxynol-9. Lancet. 1:1988;1456.
5. Kelly J.P., Reynolds R.B., Stagno S., Louv W.C., Alexander W.J. In vitro activity of the spermicide nonoxynol-9 against Chlamydia trachomatis. Antimicrob Agents Chemother. 27:1985;760-762.
6. Miller C.J., Alexander N.J., Gettie A., Hendrickx A.G., Marx P.A. The effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaques. Fertil Steril. 57:1992;1126-1128.
7. Louv W.C., Austin H., Alexander W.J., Stagno S., Cheeks J. A clinical trial of nonoxynol-9 for preventing gonococcal and chlamydial infections. J Infect Dis. 158:1988;518-523.
8. Niruthisard S., Roddy R.E., Chutivongse S. Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections. Lancet. 339:1992;1371-1375.
9. Roddy R.E., Schulz K.F., Cates W. Jr. Microbicides, meta-analysis, and the N-9 question: where's the research? Sex Transm Dis. 25:1998;151-153.
10. Rosenberg M.J., Rojanapithayakorn W., Feldblum P.J., Higgins J.E. Effect of the contraceptive sponge on chlamydial infection, gonorrhea and candidiasis. JAMA. 257:1997;2308-2312.
11. Zekeng L., Feldblum P.J., Oliver R.M., Kaptue L. Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS. 7:1993;725-731.
12. Kreiss J., Ngugi E., Holmes K.K., et al. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 268:1992;477-482.
13. Roddy R.E., Cordero M., Cordero C., Fortney J.A. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS. 4:1993;165-170.
14. Van Damme L., Niruthisard S., Atisook R., et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS. 12:1998;433-437.
15. Van Damme L., Chandeying V., Ramjee G., et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. AIDS. 14:2000;85-88.
16. Roddy R.E., Zekeng L., Ryan K.A., Tamoufé U., Weir S.S., Wong E.L. A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 339:1998;504-510.
17. Williams B., Gouws E., Wilkinson D., Karim S.A. Estimating HIV incidence rates from age prevalence data in epidemic situations. Stat Med. 20:2001;2003-2016.
18. Ghys P.D., Diallo M.O., Ettiègne-Traoré V., et al. Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers. AIDS. 15:2001;1421-1431.
19. Roddy R.E., Zekeng L., Tyan K.A., Tamoufé U., Tweedy K.G. Effect of nonoxynol-9 gel on urogenital gonorrhoea and chlamydial infection. JAMA. 287:2002;1117-1122.